PharmaPatents

Timely insight on emerging legal developments

Feed:

Tue April 23rd, 2024

The post USPTO Issues Updated Guidance on Obviousness appeared first on Foley & Lardner LLP .

Wed April 3rd, 2024

The post USPTO Stands Behind Significant New Fees for 2025 appeared first on Foley & Lardner LLP .

Wed March 27th, 2024

The post Federal Circuit Applies Safe Harbor to Imported Medical Device Samples appeared first on Foley & Lardner LLP .

Mon February 19th, 2024

The post Which Significant USPTO Fee Increases Might We See in 2025? appeared first on Foley & Lardner LLP .

Mon February 12th, 2024

The post USPTO Releases Guidance on Rule 132 Declarations appeared first on Foley & Lardner LLP .

Thu February 1st, 2024

The post Time Has Run Out for China’s 15-Day Mailing Rule appeared first on Foley & Lardner LLP .

Tue January 30th, 2024

The post Testifying on the Patent Eligibility Restoration Act appeared first on Foley & Lardner LLP .

Fri January 19th, 2024

The post USPTO Issues “Reasonable” Guidance on Enablement Under Amgen v. Sanofi appeared first on Foley & Lardner LLP .

Mon November 27th, 2023

The post How is Patent Term Extension Calculated For a Reissued Patent? appeared first on Foley & Lardner LLP .

Fri November 17th, 2023

The post Revisiting FDA’s Original Guidance on Orange Book Listability in Light of Heightened FTC Scrutiny appeared first on Foley & Lardner LLP .